Overview
MS4A1 encodes the CD20 protein, which is the target of rituximab and other therapeutic monoclonal antibodies. MS4A1 is one of a number of genes affected by aberrant somatic hypermutation in B-cell lymphomas, which complicates the interpretation of mutations at this locus. In relapsed DLBCLs, MS4A1 is sometimes mutated and these mutations have been shown to reduce CD20 expression.1
Experimental Evidence
Driver mutations affecting this gene in DLBCL have been experimentally demonstrated to cause a reduction or loss of function (LOF).1
Relevance tier by entity
| Entity | Tier | Description |
|---|---|---|
| 1 | High-confidence DLBCL gene | |
| 1 | High-confidence PMBL gene |
Mutation incidence in large patient cohorts (GAMBL reanalysis)
DLBCL
| Entity | Collection | N | mutated | Incidence | 95% CI |
|---|---|---|---|---|---|
| DLBCL | GAMBL without Reddy | 1,089 | 13 | 0.0119 | [0.0055,0.0184] |
| DLBCL | GAMBL with Reddy | 2,088 | 26 | 0.0125 | [0.0077,0.0172] |
| DLBCL | BC | 231 | 4 | 0.0173 | [5e-04,0.0341] |
| DLBCL | Dana-Farber | 303 | 2 | 0.0066 | [0,0.0157] |
| DLBCL | NCI | 470 | 7 | 0.0149 | [0.0039,0.0258] |
| DLBCL | Reddy | 999 | 13 | 0.0130 | [0.006,0.02] |
| DLBCL | DLBCL_ICGC | 85 | 0 | 0.0012 | [0,0.0085] |
Mutation pattern and selective pressure estimates
Failed to render page: conflicting chdir during another chdir block
aSHM regions
| chr_name | hg19_start | hg19_end | region | regulatory_comment |
|---|---|---|---|---|
| chr11 | 60223385 | 60225310 | TSS | active_promoter |
Cannot include /browser_MS4A1.md - does not exist yet
Expression
Failed to render page: conflicting chdir during another chdir block
